ArticleMediators of inflammation2026
Trends and Prospects in Inflammation Resolution in Acute Lung Injury and Acute Respiratory Distress Syndrome: A Bibliometric Quantitative and Visualization Analysis.
Article in Mediators of inflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundAcute lung injury and acute respiratory distress syndrome (ALI/ARDS) are common and critical pulmonary conditions involving numerous inflammatory factors and oxidative stress responses. Inflammatory responses and oxidative stress are closely related to the development of ALI/ARDS and form an important theoretical basis for treatment and drug development. Although there has been extensive research on the resolution of inflammation in ALI/ARDS, no systematic bibliometric analysis has been conducted in this field.
methodsThe researchers used bibliometrics to search the Web of Science Core Collection (WOSCC) database for research literature on the resolution of inflammation in ALI/ARDS from 2005 to 2024. Visualization mapping analysis was performed using tools such as CiteSpace and VOSviewer to analyze authors, research institutions, countries, journals, cocited literature, and keywords.
resultsA total of 375 articles were included. The research showed an upward trend, with the highest number of publications in 2022. The United States took the leading position in this field, followed by China. JIN SW had the highest number of publications, while D'Alessio FR had the highest citation count. Harvard University had the highest intermediary centrality, the American Journal of Physiology-Lung Cellular and Molecular Physiology published the most articles, and the American Journal of Respiratory and Critical Care Medicine had the highest impact factor. Resolvin D1 (RvD1) and Resolvin E1 (RvE1) played a key role in the resolution of inflammation. Drug delivery systems (DDSs), such as black phosphorus nanosheets (BPNSs) and liposomes, could efficiently deliver these mediators to enhance therapeutic effects and reduce side effects.
conclusionOver the past 20 years, interest in the resolution of inflammation in ALI/ARDS has grown. The United States has dominated research in this area. The study of RvD1 and RvE1 has become a hot topic, and the development of DDSs has provided new strategies for clinical treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.